| Literature DB >> 32671037 |
Dake Hao1,2, Hila Shimshi Swindell1,2, Lalithasri Ramasubramanian1,2, Ruiwu Liu3, Kit S Lam3, Diana L Farmer1,2, Aijun Wang1,2,4.
Abstract
The network structure and biological components of natural extracellular matrix (ECM) are indispensable for promoting tissue regeneration. Electrospun nanofibrous scaffolds have been widely used in regenerative medicine to provide structural support for cell growth and tissue regeneration due to their natural ECM mimicking architecture, however, they lack biological functions. Extracellular vesicles (EVs) are potent vehicles of intercellular communication due to their ability to transfer RNAs, proteins, and lipids, thereby mediating significant biological functions in different biological systems. Matrix-bound nanovesicles (MBVs) are identified as an integral and functional component of ECM bioscaffolds mediating significant regenerative functions. Therefore, to engineer EVs modified electrospun scaffolds, mimicking the structure of the natural EV-ECM complex and the physiological interactions between the ECM and EVs, will be attractive and promising in tissue regeneration. Previously, using one-bead one-compound (OBOC) combinatorial technology, we identified LLP2A, an integrin α4β1 ligand, which had a strong binding to human placenta-derived mesenchymal stem cells (PMSCs). In this study, we isolated PMSCs derived EVs (PMSC-EVs) and demonstrated they expressed integrin α4β1 and could improve endothelial cell (EC) migration and vascular sprouting in an ex vivo rat aortic ring assay. LLP2A treated culture surface significantly improved PMSC-EV attachment, and the PMSC-EV treated culture surface significantly enhanced the expression of angiogenic genes and suppressed apoptotic activity. We then developed an approach to enable "Click chemistry" to immobilize LLP2A onto the surface of electrospun scaffolds as a linker to immobilize PMSC-EVs onto the scaffold. The PMSC-EV modified electrospun scaffolds significantly promoted EC survival and angiogenic gene expression, such as KDR and TIE2, and suppressed the expression of apoptotic markers, such as caspase 9 and caspase 3. Thus, PMSC-EVs hold promising potential to functionalize biomaterial constructs and improve the vascularization and regenerative potential. The EVs modified biomaterial scaffolds can be widely used for different tissue engineering applications.Entities:
Keywords: electrospun nanofibrous scaffold; extracellular vesicle; integrin-based ligand; mesenchymal stem cell; tissue regeneration; vascularization
Year: 2020 PMID: 32671037 PMCID: PMC7329993 DOI: 10.3389/fbioe.2020.00633
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
Primers used for qRT-PCR.
| KDR | CCAAGAACTCCATGCCCCTTA | ATCCCTGGGATCTGAAACG |
| TIE2 | TAGAGCCTGAAACAGCATACCAGG | CTATTGGAATGGCAAATGCTGGG |
| GAPDH | ACCACAGTCCATGCCATCAC | TCCACCACCCTGTTGCTGTA |
Figure 1Characterization of PMSC-EVs. (A) TEM image of PMSC-EVs. Scale bar = 150 nm. (B) Western blot analysis of CD9, CD63, calnexin, ALIX, TSG101, integrin α4 and integrin β1 of PMSC-EVs. (C) NTA analysis of PMSC-EVs.
Figure 2Proangiogenic capacities of PMSC-EVs. (A) HUVEC migration treated with PMSC-EVs (b, d) or without PMSC-EVs (a, c). Scale bar = 100 μm. (B) Quantification of HUVEC migration area. Data were expressed as mean ± standard deviation: *p < 0.05 (n = 3). (C) Rat aortic ring assay treated with PMSC-EVs (b) or without PMSC-EVs (a). Scale bar = 500 μm. (D) Quantification of the number of sprouting per ring. Data were expressed as mean ± standard deviation: *p < 0.05 (n = 3).
Figure 3Attachment of PMSC-EVs on different treated surfaces. (A) Images of attached PMSC-EVs on untreated surface (a) and LLP2A treated surface (b). Scale bar = 5 μm. (B) Quantification of the numbers of PMSC-EVs attached on different surfaces. Data were expressed as mean ± standard deviation: **p < 0.01 (n = 5).
Figure 4Effects of PMSC-EV treated surface on angiogenic and apoptotic activity of HUVECs. (A) KDR and TIE2 expression of HUVECs cultured on untreated surface, LLP2A treated surface or PMSC-EV treated surface. (B) Caspase 3 activity of HUVECs cultured on untreated surface, LLP2A treated surface or PMSC-EV treated surface. Data are expressed as mean ± standard deviation: *p < 0.05, **p < 0.01 (n = 4).
Figure 5Schematic diagram showing the use of “Click chemistry” to introduce LLP2A to the electrospun scaffold, and the use of immobilized LLP2A to capture PMSC-EVs onto the scaffold surface.
Figure 6Effect of LLP2A modification on PMSC-EV attachment on electrospun scaffolds. (A) SEM images of PMSC-EV attachment on untreated electrospun scaffold (a), 50% LLP2A modified electrospun scaffold (b) and 100% LLP2A modified electrospun scaffold (c). Scale bar = 500 μm. (B) Quantification of the numbers of PMSC-EVs on the different modified electrospun scaffolds. Data were expressed as mean ± standard deviation: *p < 0.05 (n = 5).
Figure 7Effects of PMSC-EV modified electrospun scaffolds on angiogenic gene expression and apoptotic rate and protein expression of HUVECs. (A) Quantification of KDR and TIE2 expression of HUVECs cultured on untreated electrospun scaffolds and PMSC-EV modified electrospun scaffolds. (B) Quantification of HUVEC survival on untreated electrospun scaffolds and PMSC-EV modified electrospun scaffolds. (C) Annexin V staining of HUVECs cultured on untreated electrospun scaffolds (a) and PMSC-EV modified electrospun scaffolds (b). (D) Quantification of apoptotic rate of HUVECs cultured on untreated electrospun scaffolds and PMSC-EV modified electrospun scaffolds. (E) Quantification of caspase 9 expression of HUVECs cultured on untreated electrospun scaffolds and PMSC-EV modified electrospun scaffolds. (F) Quantification of caspase 3 expression of HUVECs cultured on untreated electrospun scaffolds and PMSC-EV modified electrospun scaffolds. Data were expressed as mean standard deviation: *p < 0.05, **p < 0.01 (n = 4).